- Home
- DIBS vs GNLX Comparison
DIBS vs GNLX Comparison
Compare DIBS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | GNLX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 133.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DIBS | GNLX |
|---|---|---|
| Price | $4.66 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 321.0K | 199.2K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | $8,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $2.50 | $2.29 |
| 52 Week High | $6.62 | $8.54 |
Technical Indicators
Market Signals| Indicator | DIBS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 43.01 |
| Support Level | $4.38 | $2.76 |
| Resistance Level | $4.83 | $3.00 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.18 | 8.97 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.